Drugs / 18F-Clofarabine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05065736 | Mar 2023 → Jun 2026 overdue | adenocarcinoma, metastatic malignant neoplasm | Roberto Vargas | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Clofarabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065736 ↗ |
| Known as | CFA | “18F-Clofarabine (CFA) is experimental because it is not approved by the Food and Drug Administration (FDA).” NCT05065736 ↗ |
| Modality | Diagnostic / imaging agent | “PET Imaging Agent” NCT05065736 ↗ |
| Route | Intravenous | “The participants will receive a CFA injection into a vein in their arm.” NCT05065736 ↗ |